Inherent Biosciences wins HealthTech Investors Pitch Competition

Salt Lake City, Utah — Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, announced today that it was selected as the winner of HealthTech Investors' Pitch Competition and the recipient of a $100k investment.

HealthTech investors (HTI) is an angel syndicate of reflective healthcare experts who invest in formidable founders working on the best solutions improving healthcare. Self described as rebels, HTI believes in radical honesty with kindness, cares little for legacy and pedigree, and values humility, perseverance, and aptitude. HTI looks for companies who are problem-focused, customer obsessed, design led, and who value distribution.

Pitch Competition

Inherent Biosciences competed with over 70 startups in the inaugural HealthTech Investors Pitch Competition. The competition progressed over three months and included a thorough and stepwise diligence process throughout.

Andy Olson, Co-founder & CEO of Inherent Biosciences commented on the experience, “There is often a lack of transparency from investors during their diligence process which can be incredibly frustrating for founders. We really appreciated the open communication of our working relationship with Rishad Usmani, MD and the team at HealthTech Investors throughout the competition.”

Diligence Process

The HTI pitch competition diligence process included:

1. Initial screening of applications by the HTI diligence team to select the Top 10

2. HTI diligence primer with key questions completed by the the Top 10 companies

3. Top 10 companies produce 5 min pitch videos and HTI investors vote for Top 3

4. One on one interviews with each company co-founder

5. Top 3 companies offer a final pitch to the competition judges which include prominent VC partners. View the final pitch competition event by clicking here

6. Extensive review of company data including financials, legals, market research, sales/marketing, product road map, IP

7. Reference check with a current investor/board member

8. Reference check with a customer

9. Follow-up diligence questions

10. All HTI Investors vote and choose the winner

Roupen Odabashian, Hematologist/Oncologist and due diligence lead for HealthTech Investors Pitch Competition said, “It has been a great journey to be part of HealthTech Investors and work with the diligence team. In the last 2 months we screened more than 70 startups. Congratulations to Inherent Biosciences for winning the pitch competition. I am very excited about what the future looks like for them and for HealthTech Investors.”

Winner Announcement

Rishad Usmani, MD, Founder of HealthTech Investors announced in a LinkedIn post, “Andy Olson and Kristin Brogaard, PhD have built something special at Inherent Biosciences, Inc. We are impressed by their fortitude, perseverance and the diligent approach they have taken. Very excited to continue working with them!”

Inherent Biosciences commented, “HealthTech Investors' passion for the future of epigenetics and personalized medicine reflects our own core strengths and values. We are proud to be innovating technologies that are helping to fill the gaps in reproductive health and provide more answers to those facing infertility. Revolutionizing healthcare is and will always be a team sport. We look forward to working together with Rishad Usmani, MD and the HealthTech team as we continue to strive for excellence!”

Let’s GO!!

About Inherent Biosciences

Inherent Biosciences, Inc. is a biotechnology company pioneering epigenetic medicine for complex diseases. Gene dysregulation, a hallmark of complex disease, has been difficult to detect and treat, until now. The company’s epigenetic platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics, biology’s inherent mechanism for gene regulation, to radically transform how we diagnose and treat complex diseases like infertility.

Connect with us on LinkedIn.